AR
Aleksandar Radujkovic
Research areas: Medicine · Hematology · Hematopoietic Stem Cell Transplantation · Acute Myeloid Leukemia Research · Chronic Myeloid Leukemia Treatments
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (11)
- Outcomes of CMML patients undergoing allo‐HCT are significantly worse compared to MDS—a study of the CMWP of the EBMT Save
- Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT Save
- Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP Save
- Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation Save
- Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT Save
- Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation Save
- Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT Save
- Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile Save
- Reply to: “Vitamin D Insufficiency May Account for Almost Nine of Ten COVID-19 Deaths: Time to Act. Comment on: Vitamin D Deficiency and Outcome of COVID-19 Patients. Nutrients 2020, 12, 2757” Save
- Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation Save
- High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience Save